Anti-PD1 therapy outcome can be predicted by pre-therapy IFN-I responsiveness of T_eff cells

Allergy. 2023 Sep;78(9):2562-2564. doi: 10.1111/all.15756. Epub 2023 May 23.

Authors

Melanie Grandits¹, Jitesh Chauhan^{1

2}, Heather J Bax^{1

2}

Affiliations

¹ St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London, UK.
² School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.

PMID: 37119458
DOI: 10.1111/all.15756

No abstract available

Publication types

News
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Inhibitors* / therapeutic use
Interferon Type I*
Interferon-gamma
T-Lymphocytes, Regulatory*

Substances

Interferon Type I
Interferon-gamma
Immune Checkpoint Inhibitors